Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study

Sara Y. Tartof(Kaiser Permanente), John M. McLaughlin(Pfizer (United States)), Sarah Simmons(Kaiser Permanente), Srinivas Rao Valluri(Pfizer (United States)), Harpreet S. Takhar(Kaiser Permanente), Timothy B. Frankland(Kaiser Permanente), Vennis Hong(Kaiser Permanente), Oluwaseye Ayoola Ogun(Kaiser Permanente), Jeff Slezak(Kaiser Permanente), Kaije Pan(Pfizer (United States)), Luis Jódar(Pfizer (United States)), Sharon Gray(Pfizer (United States)), Bradley K. Ackerson, Joann M. Zamparo(Pfizer (United States)), Laura Puzniak(Pfizer (United States))
The Lancet Regional Health - Americas
February 14, 2022
10.1016/j.lana.2022.100198
Cited by 117

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k
A Multicenter Study of ICU Telemedicine Reengineering of Adult Critical Care
|CHEST Journal|2014|219
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
|Open Forum Infectious Diseases|2022|212
Effect on Survival of Longer Intervals Between Confirmed Diagnosis and Treatment Initiation Among Low-Income Women With Breast Cancer
|Journal of Clinical Oncology|2012|211